Log in
NASDAQ:IFRX

InflaRx Stock Forecast, Price & News

$4.05
+0.06 (+1.50 %)
(As of 12/4/2020 12:00 AM ET)
Add
Compare
Today's Range
$3.96
Now: $4.05
$4.12
50-Day Range
$3.82
MA: $4.25
$5.14
52-Week Range
$2.52
Now: $4.05
$9.70
Volume109,837 shs
Average Volume770,416 shs
Market Capitalization$106.39 million
P/E RatioN/A
Dividend YieldN/A
Beta0.5
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing IFX-1 for the treatment of oncological diseases. It also develops IFX-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. InflaRx N.V. has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
InflaRx logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.26 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IFRX
CUSIPN/A
CIKN/A
Phone49-36-4150-8180
Employees43

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.99 per share

Profitability

Net Income$-59,650,000.00

Miscellaneous

Market Cap$106.39 million
Next Earnings Date5/5/2021 (Estimated)
OptionableNot Optionable
$4.05
+0.06 (+1.50 %)
(As of 12/4/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IFRX News and Ratings via Email

Sign-up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











InflaRx (NASDAQ:IFRX) Frequently Asked Questions

How has InflaRx's stock been impacted by Coronavirus (COVID-19)?

InflaRx's stock was trading at $3.23 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, IFRX shares have increased by 25.4% and is now trading at $4.05.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of InflaRx?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InflaRx in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for InflaRx
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than InflaRx?

Wall Street analysts have given InflaRx a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but InflaRx wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is InflaRx's next earnings date?

InflaRx is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for InflaRx
.

How were InflaRx's earnings last quarter?

InflaRx (NASDAQ:IFRX) announced its earnings results on Thursday, October, 29th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.36) by $0.07.
View InflaRx's earnings history
.

What price target have analysts set for IFRX?

7 equities research analysts have issued twelve-month price targets for InflaRx's shares. Their forecasts range from $7.00 to $19.00. On average, they anticipate InflaRx's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 171.6% from the stock's current price.
View analysts' price targets for InflaRx
.

Are investors shorting InflaRx?

InflaRx saw a decline in short interest in the month of October. As of October 30th, there was short interest totaling 503,100 shares, a decline of 15.1% from the October 15th total of 592,600 shares. Based on an average daily trading volume, of 355,800 shares, the days-to-cover ratio is presently 1.4 days. Approximately 2.6% of the shares of the company are sold short.
View InflaRx's Short Interest
.

Who are some of InflaRx's key competitors?

What other stocks do shareholders of InflaRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InflaRx investors own include Dynavax Technologies (DVAX), Gilead Sciences (GILD), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), AbbVie (ABBV), OPKO Health (OPK), Capricor Therapeutics (CAPR), Citius Pharmaceuticals (CTXR), Kadmon (KDMN) and Moderna (MRNA).

Who are InflaRx's key executives?

InflaRx's management team includes the following people:
  • Dr. Niels C. Riedemann M.D., Ph.D., Co-Founder, CEO & Exec. Director (Age 48)
  • Prof. Renfeng Guo, Co-Founder, Chief Scientific Officer & Exec. Director (Age 50)
  • Dr. Thomas Taapken Ph.D., Chief Financial Officer (Age 55)
  • Mr. Jordan Silverstein, Head of Corp. Devel. & Strategy
  • Dr. Maria Habel PH.D., Head of Preclinical R&D (Age 38)
  • Ms. Katrin Reiher, Head of Quality Management (Age 38)
  • Mr. Jordan Zwick, Chief Strategy Officer
  • Dr. Korinna Pilz, Global Head of Clinical R&D

When did InflaRx IPO?

(IFRX) raised $100 million in an IPO on Wednesday, November 8th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

What is InflaRx's stock symbol?

InflaRx trades on the NASDAQ under the ticker symbol "IFRX."

Who are InflaRx's major shareholders?

InflaRx's stock is owned by many different retail and institutional investors. Top institutional shareholders include Morgan Stanley (2.33%), FNY Investment Advisers LLC (1.33%), Schonfeld Strategic Advisors LLC (0.79%), Schonfeld Strategic Advisors LLC (0.79%), Raymond James Financial Services Advisors Inc. (0.18%) and Squarepoint Ops LLC (0.13%).

Which institutional investors are selling InflaRx stock?

IFRX stock was sold by a variety of institutional investors in the last quarter, including Raymond James Financial Services Advisors Inc..

Which institutional investors are buying InflaRx stock?

IFRX stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, Schonfeld Strategic Advisors LLC, Schonfeld Strategic Advisors LLC, FNY Investment Advisers LLC, and Squarepoint Ops LLC.

How do I buy shares of InflaRx?

Shares of IFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is InflaRx's stock price today?

One share of IFRX stock can currently be purchased for approximately $4.05.

How big of a company is InflaRx?

InflaRx has a market capitalization of $106.39 million. The company earns $-59,650,000.00 in net income (profit) each year or ($2.29) on an earnings per share basis. InflaRx employs 43 workers across the globe.

What is InflaRx's official website?

The official website for InflaRx is www.inflarx.de.

How can I contact InflaRx?

InflaRx's mailing address is WINZERLAER STR. 2, JENA 2M, 07745. The company can be reached via phone at 49-36-4150-8180 or via email at [email protected]

This page was last updated on 12/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.